SAN DIEGO, April 24, 2025 (GLOBE NEWSWIRE) -- A class action lawsuit has been filed on behalf of all persons and entities that purchased or otherwise acquired Treace Medical Concepts, Inc. (NASDAQ: TMCI) (“Treace Medical” or the “Company”) securities between May 8, 2023 and May 7, 2024 (the “Class Period”), charging the Company and certain senior executives with violations of the federal securities laws (collectively, “Defendants”). Treace Medical investors have until June 10, 2025 to seek appointment as le ...

Core Viewpoint - A class action has been filed against Treace Medical Concepts, Inc. for allegedly misleading investors about the demand for its primary product, the Lapiplasty 3D Bunion Correction System, leading to a significant decline in stock price [1][2]. Group 1: Allegations and Impact - The complaint alleges that Treace Medical failed to disclose competition's impact on the demand for its primary product, resulting in a revenue decline [2]. - Following the revelation of these facts, Treace Medical's stock price fell nearly 63%, closing at $4.17 per share on May 8, 2024 [2]. Group 2: Class Action Participation - Shareholders may be eligible to participate in the class action, with a deadline to file as lead plaintiff by June 10, 2025 [3]. - Shareholders can choose to remain absent class members without participating in the case [3]. Group 3: Company Background - Robbins LLP is a recognized leader in shareholder rights litigation, dedicated to helping shareholders recover losses and improve corporate governance since 2002 [4].

Core Viewpoint - Treace Medical Concepts, Inc. (NASDAQ: TMCI) is facing a class action lawsuit due to allegations of issuing materially false and misleading statements regarding its primary product, the 3D bunion correction system, "Lapiplasty" [3]. Group 1: Allegations and Impact - The lawsuit claims that competition negatively affected the demand and utilization of the Lapiplasty system [3]. - As a result of the competition, Treace Medical's revenue declined, prompting the company to accelerate plans for an alternative product to osteotomy [3]. - Defendants allegedly made positive statements about the company's business and prospects that were materially misleading and lacked a reasonable basis [3]. Group 2: Class Action Details - The class period for the lawsuit is from May 8, 2023, to May 7, 2024 [3]. - Shareholders who purchased TMCI shares during this period are encouraged to register for the class action, with a deadline of June 10, 2025, to seek lead plaintiff status [4]. - Participants will be enrolled in a portfolio monitoring software to receive updates throughout the case lifecycle [4].

Core Viewpoint - A class action lawsuit has been filed against Treace Medical Concepts, Inc for alleged securities fraud and unlawful business practices [2]. Group 1: Lawsuit Details - The lawsuit involves Treace Medical and certain officers and/or directors accused of engaging in securities fraud or other unlawful business practices [2]. - Investors who purchased Treace Medical securities during the Class Period can request to be appointed as Lead Plaintiff by June 10, 2025 [3]. Group 2: Financial Performance - On May 7, 2024, Treace Medical lowered its full-year 2024 revenue guidance from a range of $220 million to $225 million down to $201 million to $211 million [3]. - The company cited competition from minimally invasive osteotomy and Lapiplasty "knockoffs" as headwinds affecting Lapiplasty growth [3]. Group 3: Stock Market Reaction - Following the revenue guidance reduction, Treace Medical's stock price fell by $6.95, or nearly 63%, closing at $4.17 per share on May 8, 2024, with unusually high trading volume [4].

Core Viewpoint - Treace Medical Concepts, Inc. is facing a class action securities lawsuit due to alleged securities fraud impacting investors between May 8, 2023, and May 7, 2024 [1] Group 1: Allegations and Impact - The lawsuit claims that Treace Medical's primary product, the 3D bunion correction system "Lapiplasty," was negatively affected by competition, leading to a decline in revenue [2] - As a result of the revenue decline, Treace Medical needed to expedite plans for an alternative product to osteotomy [2] - The defendants allegedly made misleading positive statements regarding the company's business and prospects, which lacked a reasonable basis [2] Group 2: Legal Process and Participation - Investors who suffered losses during the specified timeframe have until June 10, 2025, to request to be appointed as lead plaintiff [3] - Class members may be entitled to compensation without any out-of-pocket costs or fees [3] Group 3: Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions for shareholders over the past 20 years [4] - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as a leading securities litigation firm in the U.S. [4]

Core Viewpoint - A class action lawsuit has been filed against Treace Medical Concepts, Inc. for allegedly misleading investors about the demand for its primary product, the Lapiplasty 3D Bunion Correction System, leading to a significant decline in stock price [1][2]. Group 1: Allegations and Impact - The complaint alleges that Treace Medical failed to disclose competition's impact on the demand and utilization of its primary product [2] - As a result of these undisclosed factors, Treace Medical's revenue declined, prompting the company to accelerate plans for an alternative product to osteotomy [2] - Following the revelation of these issues, Treace Medical's stock price fell nearly 63%, closing at $4.17 per share on May 8, 2024 [2] Group 2: Class Action Participation - Shareholders may be eligible to participate in the class action against Treace Medical and must file their papers by June 10, 2025, to serve as lead plaintiff [3] - Shareholders can choose to remain absent class members without participating in the case and still be eligible for recovery [3] Group 3: Company Background - Robbins LLP is a recognized leader in shareholder rights litigation, dedicated to helping shareholders recover losses and improve corporate governance since 2002 [4]

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Treace Medical Concepts, Inc. regarding a class action lawsuit due to alleged misleading statements and failure to disclose critical information during the class period from May 8, 2023, to May 7, 2024 [1] Group 1: Allegations - The complaint alleges that competition negatively affected the demand and utilization of Treace Medical's primary product, the 3D bunion correction system known as "Lapiplasty" [1] - As a result of the competition, Treace Medical's revenue declined, prompting the company to expedite plans for an alternative product to osteotomy [1] - The defendants' positive statements about the company's business, operations, and prospects were claimed to be materially misleading and lacked a reasonable basis [1] Group 2: Class Action Details - Shareholders who purchased shares of TMCI during the specified class period are encouraged to register for the class action, with a deadline of June 10, 2025, to seek lead plaintiff status [2] - Once registered, shareholders will be enrolled in a portfolio monitoring software to receive updates throughout the case lifecycle [2] - Participation in the case incurs no cost or obligation for the shareholders [2] Group 3: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting the rights of investors affected by deceit, fraud, and illegal business practices [3] - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements or omissions that inflated stock prices [3]

Group 1 - A class action lawsuit has been filed against Treace Medical Concepts, Inc. for securities purchased between May 8, 2023, and May 7, 2024 [1] - Investors who purchased Treace Medical securities during the class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - The lawsuit alleges that Treace Medical made false or misleading statements regarding competition affecting the demand for its primary product, the Lapiplasty 3D Bunion Correction System, leading to a decline in revenue [5] Group 2 - The Rosen Law Firm, which is representing the investors, has a strong track record in securities class actions, having secured over $438 million for investors in 2019 alone [4] - The firm has been recognized for its success in securities class action settlements, being ranked No. 1 by ISS Securities Class Action Services in 2017 [4] - Investors can join the class action by submitting a form or contacting the firm directly for more information [3][6]

Core Viewpoint - A class action securities lawsuit has been filed against Treace Medical Concepts, Inc. alleging securities fraud affecting investors between May 8, 2023, and May 7, 2024 [1][2]. Group 1: Allegations and Impact - The lawsuit claims that Treace Medical's primary product, the 3D bunion correction system known as "Lapiplasty," faced decreased demand due to competition [2]. - As a result of the competition, Treace Medical's revenue declined, prompting the company to expedite plans for an alternative product to osteotomy [2]. - The defendants are accused of making materially misleading positive statements regarding the company's business and prospects [2]. Group 2: Legal Process and Participation - Investors who suffered losses during the specified timeframe have until June 10, 2025, to request to be appointed as lead plaintiff [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States [4].

Core Viewpoint - A class action securities lawsuit has been filed against Treace Medical Concepts, Inc. due to alleged securities fraud impacting investors between May 8, 2023, and May 7, 2024 [1] Group 1: Allegations and Impact - The lawsuit claims that Treace Medical Concepts made false statements regarding the demand and utilization of its primary product, the 3D bunion correction system known as "Lapiplasty" [2] - It is alleged that competition negatively affected the company's revenue, prompting the need to accelerate plans for an alternative product to osteotomy [2] - The defendants' positive statements about the company's business and prospects were reportedly misleading and lacked a reasonable basis [2] Group 2: Legal Process and Participation - Investors who suffered losses during the specified timeframe have until June 10, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require this role [3] - Class members may be entitled to compensation without incurring any out-of-pocket costs or fees [3] Group 3: Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years [4] - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the United States [4]